Lynch syndrome (LS), also known as Hereditary Non-Polyposis Colorectal Cancer (HNPCC), is the most common hereditary colorectal (CRC) cancer predisposition syndrome. It is an autosomal dominant condition that causes a significant increased lifetime risk of CRC and endometrial (uterine) cancer in addition to other cancers. Individuals suspected of having LS should be referred for a genetic consultation for consideration of genetic testing. Screening, surveillance and management of CRC and other cancers should be guided by genetic test results and/or family/ personal history. Studies show that conversations between patients and their healthcare providers are the strongest driver of screening participation. (For more information see the GECKO Messenger).
This point of care tool has two parts. The first part contains three questions for your patient that will better help you stratify his/her risk for hereditary colorectal cancer and to identify those that would benefit from a referral for genetics consultation. The cumulative sensitivity of these three questions in identifying patients with characteristics suggestive of the hereditary colorectal cancer syndrome, Lynch syndrome (LS), and those who should undergo a more extensive risk assessment is 77%. When all 3 questions are answered “yes,” the tool correctly identifies 95% of individuals with germline mutations causing LS.1 If a patient answers “yes” to all of these questions a referral to genetics should be offered. If a patient answers “yes” to any of these questions, consider further assessment using the criteria in Part II. Part II contains further personal and family history Red Flags to identify those at high risk of LS most likely to benefit from a referral to genetics. These red flags are derived from the Amsterdam criteria [with 22% sensitivity and 98% specificity for LS] and the revised Bethesda criteria [with a 82% sensitivity and 77% specificity for LS].2
Find your local genetics program here.
[1] Kastrinos F, Allen JI, Stockwell DH, et al., Development and validation of a colon cancer risk assessment tool for patients undergoing colonoscopy. Am J Gastroenterol 2009; 104: 1508–1518.
[2] Giardiello FM, Allen JI, Axilbund JE et al., Guidelines on genetic evaluation and management of Lynch syndreom: A consensus by the US multi-society task force on colorectal cancer. Dis Colon Rectum 2014; 57: 1025–1048
–
Disclaimer:
· GECKO is an independent not-for-profit program that does not accept support from commercial or non-academic entities.
· GECKO aims to aid the practicing non-genetics clinician by providing informed resources regarding genetic/genomic conditions, services and technologies that have been developed in a rigorous and evidence-based manner with periodic updating. The content on the GECKO site is for educational purposes only. No resource should be used as a substitute for clinical judgement. GECKO assumes no responsibility or liability resulting from the use of information contained herein.
· All clinicians using this site are encouraged to consult local genetics clinics, medical geneticists, or specialists for clarification of questions that arise relating to specific patient problems.
· All patients should seek the advice of their own physician or other qualified clinician regarding any medical questions or conditions.
· External links are selected and reviewed at the time a page is published. However, GECKO is not responsible for the content of external websites. The inclusion of a link to an external website from GECKO should not be understood to be an endorsement of that website or the site’s owners (or their products/services).
· We strive to provide accurate, timely, unbiased, and up-to-date information on this site, and make every attempt to ensure the integrity of the site. However, it is possible that the information contained here may contain inaccuracies or errors for which neither GECKO nor its funding agencies assume responsibility.
